Evidence map›Paper›PMID 37212934›Full record

ReviewCurrent treatment options in oncology2023

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.

Katleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, Ken Op de Beeck, Guy Van Camp, Helena Oliveres, Hans Prenen, Timon Vandamme, Marc Peeters

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Katleen JanssensCenter of Medical Genetics, University of Antwerp and Antwerp University Hospital, Prins Boudewijnlaan 43/6, 2650, Edegem, Belgium.ORCID 0000-0003-3987-4592
Chinouk LambrechtsDepartment of Oncology and Multidisciplinary Oncological Center of Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium.
Barbara GeerinckxDepartment of Oncology and Multidisciplinary Oncological Center of Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium.ORCID 0000-0002-7687-2273
Ken Op de BeeckCenter of Medical Genetics, University of Antwerp and Antwerp University Hospital, Prins Boudewijnlaan 43/6, 2650, Edegem, Belgium.ORCID 0000-0001-5527-6838
Guy Van CampCenter of Medical Genetics, University of Antwerp and Antwerp University Hospital, Prins Boudewijnlaan 43/6, 2650, Edegem, Belgium.ORCID 0000-0001-5105-9000
Helena OliveresDepartment of Oncology and Multidisciplinary Oncological Center of Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium.ORCID 0000-0003-1801-1181
Hans PrenenIntegrated Personalized and Precision Oncology Network (IPPON), Center for Oncological Research (CORE), University of Antwerp and Antwerp University Hospital, Universiteitsplein 1, 2610, Wilrijk, Belgium.ORCID 0000-0001-8802-7352
Timon VandammeIntegrated Personalized and Precision Oncology Network (IPPON), Center for Oncological Research (CORE), University of Antwerp and Antwerp University Hospital, Universiteitsplein 1, 2610, Wilrijk, Belgium. timon.vandamme@uza.be.ORCID 0000-0003-3701-5305
Marc PeetersIntegrated Personalized and Precision Oncology Network (IPPON), Center for Oncological Research (CORE), University of Antwerp and Antwerp University Hospital, Universiteitsplein 1, 2610, Wilrijk, Belgium.ORCID 0000-0003-4969-2303
University of Antwerp · BEAntwerp University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementOne of the great challenges in digestive oncology is choosing the optimal therapy for RAS-mutated metastatic colorectal cancer (mCRC). Even though the RAS genes and accompanying pathway were identified decades ago and extensive knowledge exists on their role in carcinogenesis, it has proven challenging to translate these insights into new therapies and clinical benefit for patients. However, recently, new drugs targeting this pathway (for example, KRAS

Indexed as

Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsAntibodies, MonoclonalErbB ReceptorsHumansMutationProto-Oncogene Proteins p21(ras)Antibodies, MonoclonalErbB ReceptorsProto-Oncogene Proteins p21(ras)KRASG12C-inhibitorsMetastatic colorectal cancerRAS mutationTargeted therapy

Identifiers

PMID37212934
OpenAlexW4377220167

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.